Display options
Cite
Li LY, Ma RL, Du L, et al. Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients. Open Access Rheumatol. 2017;9:159-165doi: 10.2147/OARRR.S119749.
Li, L. Y., Ma, R. L., Du, L., & Wu, A. S. (2017). Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients. Open access rheumatology : research and reviews, 9159-165. https://doi.org/10.2147/OARRR.S119749
Li, Lian-Yun, et al. "Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients." Open access rheumatology : research and reviews vol. 9 (2017): 159-165. doi: https://doi.org/10.2147/OARRR.S119749
Li LY, Ma RL, Du L, Wu AS. Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients. Open Access Rheumatol. 2017 Aug 11;9:159-165. doi: 10.2147/OARRR.S119749. eCollection 2017. PMID: 28860878; PMCID: PMC5565251.
Copy Download .nbib Format: NLM
Share it on

Open Access Rheumatol. 2017 Aug 11;9:159-165. doi: 10.2147/OARRR.S119749. eCollection 2017.

Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty patients.

Open access rheumatology : research and reviews

Lian-Yun Li, Ruo-Lan Ma, Liqin Du, An-Shi Wu

Affiliations

  1. Department of Anesthesiology, Dongfang Hospital of Beijing University of Chinese Medicine.
  2. Department of Pain, Beijing Electric Power Hospital.
  3. Department of Anesthesiology, Beijing Stomatological Hospital, Capital Medical University, Beijing, People's Republic of China.
  4. Department of Chemistry & Biochemistry, Texas State University, San Marcos, TX, USA.
  5. Department of Anesthesiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China.

PMID: 28860878 PMCID: PMC5565251 DOI: 10.2147/OARRR.S119749

Abstract

OBJECTIVES: Ozonated autohemotherapy (O3-AHT) has been used to effectively treat gout, but the underlying therapeutic mechanisms remain unknown. In this study, as an initial effort to understand the therapeutic mechanisms of O3-AHT, we aim to examine the effect of O3-AHT on serum inflammatory cytokine levels in gouty patients.

PATIENTS AND METHODS: Three groups of patients and healthy subjects were recruited, including the gouty (n=10), hyperuricemia (n=10), and healthy control (n=11) groups. Cytometric bead array was applied to examine 12 cytokines before (T0), during (T1), and after (T2) therapies.

RESULTS: Three cytokines, IL-8, IL-12, and MCP-1, were detectable in all participants. Before O3-AHT, the average serum levels of IL-8 and MCP-1 were higher in the gout group than in the hyperuricemia and healthy control groups, confirming the inflammation status in gouty patients. After the 5th course of O3-AHT (T1), IL-8 level was significantly increased compared to that at T0. IL-12 level was also raised at T1, although the difference did not reach statistical significance. After completing the therapy, both IL-8 and IL-12 levels decreased to levels lower than those at T0. MCP-1 level remained essentially unchanged during and after treatment.

CONCLUSION: Our results indicate that O3-AHT induces a significant change in serum cytokine levels, suggesting that modulating the inflammatory process is one of the therapeutic mechanisms underlying O3-AHT. In addition, the sensitive response of serum IL-8 and IL-12 levels to O3-AHT suggests that these cytokines may be developed as biomarkers to evaluate the therapeutic effect of O3-AHT in gouty patients.

Keywords: cytokine; gout; inflammation; ozonated autohemotherapy

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Rheumatol Int. 2006 Jan;26(3):274-6 - PubMed
  2. J Altern Complement Med. 2011 Mar;17(3):259-63 - PubMed
  3. Arthritis Rheumatol. 2014 Sep;66(9):2423-8 - PubMed
  4. Arthritis Res Ther. 2010;12(1):R23 - PubMed
  5. Dtsch Arztebl Int. 2009 Aug;106(34-35):549-55 - PubMed
  6. Semin Immunopathol. 2013 Jul;35(4):501-12 - PubMed
  7. Curr Opin Rheumatol. 2015 Mar;27(2):170-4 - PubMed
  8. J Biol Regul Homeost Agents. 1998 Jul-Sep;12(3):67-75 - PubMed
  9. Lancet. 2011 Jan 8;377(9760):165-77 - PubMed
  10. Ann Rheum Dis. 2004 Oct;63(10):1351-2 - PubMed
  11. Curr Opin Rheumatol. 2010 Mar;22(2):165-72 - PubMed
  12. Rheumatology (Oxford). 2013 Jun;52(6):1018-21 - PubMed
  13. Ann Biomed Eng. 2015 Sep;43(9):2207-19 - PubMed
  14. Ann Rheum Dis. 2006 Oct;65(10):1301-11 - PubMed
  15. Scand J Rheumatol. 2013;42(2):150-8 - PubMed
  16. Med Health R I. 2009 Nov;92(11):363-4, 368 - PubMed
  17. Arthritis Rheum. 1998 May;41(5):900-9 - PubMed
  18. Rheum Dis Clin North Am. 2014 May;40(2):155-75 - PubMed
  19. JAMA. 2015 Jun 9;313(22):2276-7 - PubMed
  20. Ann Rheum Dis. 2009 Oct;68(10):1602-8 - PubMed
  21. Curr Opin Rheumatol. 2010 Mar;22(2):144-51 - PubMed
  22. Immunol Invest. 2016 Jul;45(5):383-95 - PubMed
  23. Arthritis Res Ther. 2010;12 (2):206 - PubMed
  24. Arthritis Rheumatol. 2015 Dec;67(12):3303-13 - PubMed
  25. Oral Oncol. 2011 Mar;47(3):185-90 - PubMed
  26. Exp Ther Med. 2014 Nov;8(5):1423-1427 - PubMed
  27. J Leukoc Biol. 1997 Oct;62(4):444-9 - PubMed

Publication Types